|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nagasue N, Kohno H, Chang YC, Taniura H,
Yamanoi A, Uchida M, Kimoto T, Takemoto Y, Nakamura T and Yukaya H:
Liver resection for hepatocellular carcinoma. Results of 229
consecutive patients during 11 years. Ann Surg. 217:375–384. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Takenaka K, Kawahara N, Yamamoto K,
Kajiyama K, Maeda T, Itasaka H, Shirabe K, Nishizaki T, Yanaga K
and Sugimachi K: Results of 280 liver resections for hepatocellular
carcinoma. Arch Surg. 131:71–76. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar
|
|
5
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dawkins J and Webster RM: The
hepatocellular carcinoma market. Nat Rev Drug Discov. 18:13–14.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wong CM, Fan ST and Ng IO: beta-Catenin
mutation and over-expression in hepatocellular carcinoma:
Clinicopathologic and prognostic significance. Cancer. 92:136–145.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Endo K, Ueda T, Ueyama J, Ohta T and
Terada T: Immunoreactive E-cadherin, alpha-catenin, beta-catenin,
and gamma-catenin proteins in hepatocellular carcinoma:
Relationships with tumor grade, clinicopathologic parameters, and
patients' survival. Hum Pathol. 31:558–565. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Inagawa S, Itabashi M, Adachi S, Kawamoto
T, Hori M, Shimazaki J, Yoshimi F and Fukao K: Expression and
prognostic roles of beta-catenin in hepatocellular carcinoma:
Correlation with tumor progression and postoperative survival. Clin
Cancer Res. 8:450–456. 2002.PubMed/NCBI
|
|
10
|
Hoshida Y, Nijman SM, Kobayashi M, Chan
JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K,
Hashimoto M, et al: Integrative transcriptome analysis reveals
common molecular subclasses of human hepatocellular carcinoma.
Cancer Res. 69:7385–7392. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lachenmayer A, Alsinet C, Savic R,
Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell
P, Tsai HW, et al: Wnt-pathway activation in two molecular classes
of hepatocellular carcinoma and experimental modulation by
sorafenib. Clin Cancer Res. 18:4997–5007. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Taniguchi K, Roberts LR, Aderca IN, Dong
X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI,
et al: Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in
hepatocellular carcinomas and hepatoblastomas. Oncogene.
21:4863–4871. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bengochea A, de Souza MM, Lefrançois L, Le
Roux E, Galy O, Chemin I, Kim M, Wands JR, Trepo C, Hainaut P, et
al: Common dysregulation of Wnt/Frizzled receptor elements in human
hepatocellular carcinoma. Br J Cancer. 99:143–150. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Neil BH, Goff LW, Kauh JS, Strosberg JR,
Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, et
al: Phase II study of the mitogen-activated protein kinase 1/2
inhibitor selumetinib in patients with advanced hepatocellular
carcinoma. J Clin Oncol. 29:2350–2356. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iverson C, Larson G, Lai C, Yeh LT, Dadson
C, Weingarten P, Appleby T, Vo T, Maderna A, Vernier JM, et al:
RDEA119/BAY 869766: A potent, selective, allosteric inhibitor of
MEK1/2 for the treatment of cancer. Cancer Res. 69:6839–6847. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lim HY, Heo J, Choi HJ, Lin CY, Yoon JH,
Hsu C, Rau KM, Poon RT, Yeo W, Park JW, et al: A phase II study of
the efficacy and safety of the combination therapy of the MEK
inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian
patients with unresectable hepatocellular carcinoma. Clin Cancer
Res. 20:5976–5985. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tai WM, Yong WP, Lim C, Low LS, Tham CK,
Koh TS, Ng QS, Wang WW, Wang LZ, Hartano S, et al: A phase Ib study
of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib
in advanced hepatocellular carcinoma (HCC). Ann Oncol.
27:2210–2215. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huynh H, Soo KC, Chow PK, Panasci L and
Tran E: Xenografts of human hepatocellular carcinoma: A useful
model for testing drugs. Clin Cancer Res. 12:4306–4314. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals: Guide for the Care and Use of Laboratory Animals. 8th
edition. National Academies Press; US, Washington, DC: 2011
|
|
20
|
Huynh H, Chow PK, Palanisamy N,
Salto-Tellez M, Goh BC, Lee CK, Somani A, Lee HS, Kalpana R, Yu K,
et al: Bevacizumab and rapamycin induce growth suppression in mouse
models of hepatocellular carcinoma. J Hepatol. 49:52–60. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huynh H, Ngo VC, Koong HN, Poon D, Choo
SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, et al: AZD6244
enhances the anti-tumor activity of sorafenib in ectopic and
orthotopic models of human hepatocellular carcinoma (HCC). J
Hepatol. 52:79–87. 2010. View Article : Google Scholar
|
|
22
|
Huynh H, Lee LY, Goh KY, Ong R, Hao H-X,
Huang A, Wang Y, Graus Porta D, Chow P and Chung A: Infigratinib
mediates vascular normalization, impairs metastasis and improves
chemotherapy in hepatocellular carcinoma. Hepatology. Dec 21–2018,
Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Červenka I, Wolf J, Mašek J, Krejci P,
Wilcox WR, Kozubík A, Schulte G, Gutkind JS and Bryja V:
Mitogen-activated protein kinases promote WNT/beta-catenin
signaling via phosphorylation of LRP6. Mol Cell Biol. 31:179–189.
2011. View Article : Google Scholar
|
|
24
|
Brembeck FH, Rosário M and Birchmeier W:
Balancing cell adhesion and Wnt signaling, the key role of
beta-catenin. Curr Opin Genet Dev. 16:51–59. 2006. View Article : Google Scholar
|
|
25
|
Krejci P, Aklian A, Kaucka M, Sevcikova E,
Prochazkova J, Masek JK, Mikolka P, Pospisilova T, Spoustova T,
Weis M, et al: Receptor tyrosine kinases activate canonical
WNT/β-catenin signaling via MAP kinase/LRP6 pathway and direct
β-catenin phosphorylation. PLoS One. 7:e358262012. View Article : Google Scholar
|
|
26
|
Hendriksen J, Fagotto F, van der Velde H,
van Schie M, Noordermeer J and Fornerod M: RanBP3 enhances nuclear
export of active (beta)-catenin independently of CRM1. J Cell Biol.
171:785–797. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pokutta S and Weis WI: Structure of the
dimerization and beta-catenin-binding region of alpha-catenin. Mol
Cell. 5:533–543. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de La Coste A, Romagnolo B, Billuart P,
Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C,
Kahn A, et al: Somatic mutations of the beta-catenin gene are
frequent in mouse and human hepatocellular carcinomas. Proc Natl
Acad Sci USA. 95:8847–8851. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Miyoshi Y, Iwao K, Nagasawa Y, Aihara T,
Sasaki Y, Imaoka S, Murata M, Shimano T and Nakamura Y: Activation
of the beta-catenin gene in primary hepatocellular carcinomas by
somatic alterations involving exon 3. Cancer Res. 58:2524–2527.
1998.PubMed/NCBI
|
|
30
|
Laurent-Puig P and Zucman-Rossi J:
Genetics of hepatocellular tumors. Oncogene. 25:3778–3786. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Katoh M: Canonical and non-canonical WNT
signaling in cancer stem cells and their niches: Cellular
heterogeneity, omics reprogramming, targeted therapy and tumor
plasticity (Review). Int J Oncol. 51:1357–1369. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He TC, Sparks AB, Rago C, Hermeking H,
Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW:
Identification of c-MYC as a target of the APC pathway. Science.
281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pez F, Lopez A, Kim M, Wands JR, Caron de
Fromentel C and Merle P: Wnt signaling and hepatocarcinogenesis:
molecular targets for the development of innovative anticancer
drugs. J Hepatol. 59:1107–1117. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vilchez V, Turcios L, Marti F and Gedaly
R: Targeting Wnt/β-catenin pathway in hepatocellular carcinoma
treatment. World J Gastroenterol. 22:823–832. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Delgado ER, Yang J, So J, Leimgruber S,
Kahn M, Ishitani T, Shin D, Mustata Wilson G and Monga SP:
Identification and characterization of a novel small-molecule
inhibitor of β-catenin signaling. Am J Pathol. 184:2111–2122. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gedaly R, Galuppo R, Daily MF, Shah M,
Maynard E, Chen C, Zhang X, Esser KA, Cohen DA, Evers BM, et al:
Targeting the Wnt/β-catenin signaling pathway in liver cancer stem
cells and hepatocellular carcinoma cell lines with FH535. PLoS One.
9:e992722014. View Article : Google Scholar
|
|
37
|
Handeli S and Simon JA: A small-molecule
inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma
and PPARdelta activities. Mol Cancer Ther. 7:521–529. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Galuppo R, Maynard E, Shah M, Daily MF,
Chen C, Spear BT and Gedaly R: Synergistic inhibition of HCC and
liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and
WNT/β-catenin pathways. Anticancer Res. 34:1709–1713.
2014.PubMed/NCBI
|
|
39
|
Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH
and Cheng AL: Inhibition of the Wnt/β-catenin signaling pathway
improves the anti-tumor effects of sorafenib against hepatocellular
carcinoma. Cancer Lett. 381:58–66. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Aberle H, Schwartz H, Hoschuetzky H and
Kemler R: Single amino acid substitutions in proteins of the
armadillo gene family abolish their binding to alpha-catenin. J
Biol Chem. 271:1520–1526. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Roura S, Miravet S, Piedra J, García de
Herreros A and Duñach M: Regulation of E-cadherin/Catenin
association by tyrosine phosphorylation. J Biol Chem.
274:36734–36740. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Piedra J, Miravet S, Castaño J, Pálmer HG,
Heisterkamp N, García de Herreros A and Duñach M: p120
Catenin-associated Fer and Fyn tyrosine kinases regulate
beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin
Interaction. Mol Cell Biol. 23:2287–2297. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Piedra J, Martinez D, Castano J, Miravet
S, Dunach M and de Herreros AG: Regulation of beta-catenin
structure and activity by tyrosine phosphorylation. J Biol Chem.
276:20436–20443. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brembeck FH, Schwarz-Romond T, Bakkers J,
Wilhelm S, Hammerschmidt M and Birchmeier W: Essential role of
BCL9-2 in the switch between beta-catenin's adhesive and
transcriptional functions. Genes Dev. 18:2225–2230. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li Y, Lu W, He X, Schwartz AL and Bu G:
LRP6 expression promotes cancer cell proliferation and
tumorigenesis by altering beta-catenin subcellular distribution.
Oncogene. 23:9129–9135. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Austinat M, Dunsch R, Wittekind C,
Tannapfel A, Gebhardt R and Gaunitz F: Correlation between
beta-catenin mutations and expression of Wnt-signaling target genes
in hepatocellular carcinoma. Mol Cancer. 7:212008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Boyault S, Rickman DS, de Reyniès A,
Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti
J, Franco D, et al: Transcriptome classification of HCC is related
to gene alterations and to new therapeutic targets. Hepatology.
45:42–52. 2007. View Article : Google Scholar
|
|
48
|
Cleary SP, Jeck WR, Zhao X, Chen K,
Selitsky SR, Savich GL, Tan TX, Wu MC, Getz G, Lawrence MS, et al:
Identification of driver genes in hepatocellular carcinoma by exome
sequencing. Hepatology. 58:1693–1702. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Guichard C, Amaddeo G, Imbeaud S, Ladeiro
Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M,
Degos F, et al: Integrated analysis of somatic mutations and focal
copy-number changes identifies key genes and pathways in
hepatocellular carcinoma. Nat Genet. 44:694–698. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kan Z, Zheng H, Liu X, Li S, Barber TD,
Gong Z, Gao H, Hao K, Willard MD, Xu J, et al: Whole-genome
sequencing identifies recurrent mutations in hepatocellular
carcinoma. Genome Res. 23:1422–1433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Aberle H, Bauer A, Stappert J, Kispert A
and Kemler R: beta-catenin is a target for the ubiquitin-proteasome
pathway. EMBO J. 16:3797–3804. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Liu C, Li Y, Semenov M, Han C, Baeg GH,
Tan Y, Zhang Z, Lin X and He X: Control of beta-catenin
phosphorylation/degradation by a dual-kinase mechanism. Cell.
108:837–847. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Orford K, Crockett C, Jensen JP, Weissman
AM and Byers SW: Serine phosphorylation-regulated ubiquitination
and degradation of beta-catenin. J Biol Chem. 272:24735–24738.
1997. View Article : Google Scholar : PubMed/NCBI
|
